What is ReCode Therapeutics?
ReCode Therapeutics is a clinical-stage biotechnology firm dedicated to the development of next-generation genetic medicines. At the core of its innovation is the proprietary SORT lipid nanoparticle platform, a sophisticated delivery system designed to transport genetic payloads with high precision. By overcoming traditional barriers in drug delivery, the company is uniquely positioned to treat a broad spectrum of rare and common diseases. Its market position is bolstered by a robust pipeline and a strategic focus on enhancing the efficacy and safety profiles of genetic therapies, effectively bridging the gap between complex molecular science and patient-centric clinical outcomes.
How much funding has ReCode Therapeutics raised?
ReCode Therapeutics has raised a total of $415.4M across 6 funding rounds:
Angel/Seed
$2M
Series A
$80M
Private Equity
$15M
Series B
$260M
Other Financing Round
$29M
Debt
$29.4M
Angel/Seed (2019): $2M, investors not publicly disclosed
Series A (2020): $80M led by Hunt Technology Ventures, OrbiMed, Osage University Partners, Colt Ventures, Vida Ventures, and MPM BioImpact
Private Equity (2023): $15M supported by Cystic Fibrosis Foundation
Series B (2023): $260M featuring Superstring Capital, Solasta Ventures, NS Investment, Hunt Technology Ventures, Osage University Partners, BLV, Tekla Healthcare Opportunities, Vida Ventures, EcoR1 Capital, Sanofi Ventures, MPM BioImpact, Colt Ventures, Pfizer, and OrbiMed
Other Financing Round (2025): $29M, investors not publicly disclosed
Debt (2025): $29.4M, investors not publicly disclosed
Key Investors in ReCode Therapeutics
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms to support innovation at various stages of development.
Osage University Partners
Osage University Partners is a venture capital firm that exclusively invests in innovative startups emerging from leading universities and research institutions, bridging the gap between academic research and commercial application.
Vida Ventures
Vida Ventures is a life sciences investment firm founded by scientists and entrepreneurs, dedicated to funding breakthroughs in biomedicine and advancing transformative innovations for patients.
What's next for ReCode Therapeutics?
With the recent influx of capital, ReCode Therapeutics is well-positioned to accelerate its clinical development programs and expand the utility of its SORT platform. The company is expected to prioritize the advancement of its lead candidates through rigorous human trials while simultaneously exploring new therapeutic indications. As the firm transitions into a more mature phase of its lifecycle, the focus will likely shift toward scaling manufacturing capabilities and fostering strategic partnerships with global pharmaceutical entities to ensure the successful commercialization of its genetic medicine portfolio.
See full ReCode Therapeutics company page
